$607 Million is the total value of NEXTHERA CAPITAL LP's 40 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 169.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | Buy | Allergan PLC | $41,840,000 | +23.0% | 248,620 | +19.6% | 6.89% | +9.9% |
| BMY | New | Bristol-Myers Squibb Co | $21,657,000 | – | 342,399 | +100.0% | 3.57% | – |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $21,016,000 | +43.7% | 259,235 | +58.1% | 3.46% | +28.4% |
| INSM | Buy | Insmed Inc | $20,685,000 | +33.0% | 918,523 | +84.1% | 3.41% | +18.8% |
| SGEN | New | Seattle Genetics Inc | $18,998,000 | – | 362,974 | +100.0% | 3.13% | – |
| CORT | New | Corcept Therapeutics Inc | $17,193,000 | – | 1,045,196 | +100.0% | 2.83% | – |
| AZN | New | AstraZeneca PLCsponsored adr | $16,925,000 | – | 484,000 | +100.0% | 2.79% | – |
| IMMU | Buy | Immunomedics Inc | $15,799,000 | +141.7% | 1,081,410 | +167.3% | 2.60% | +115.9% |
| DOVA | Buy | Dova Pharmaceuticals Inc | $15,411,000 | +18.1% | 568,243 | +25.4% | 2.54% | +5.5% |
| GBT | Buy | Global Blood Therapeutics Inc | $15,222,000 | +24.2% | 315,147 | +1.2% | 2.51% | +10.9% |
| SGMO | Buy | Sangamo Therapeutics Inc | $14,941,000 | +28.6% | 786,376 | +11.0% | 2.46% | +14.8% |
| PCRX | New | Pacira Pharmaceuticals Inc/DE | $14,909,000 | – | 478,620 | +100.0% | 2.46% | – |
| CBIO | Buy | Catalyst Biosciences Inc | $13,896,000 | +227.4% | 538,624 | +73.1% | 2.29% | +192.6% |
| CLVS | Buy | Clovis Oncology Inccall | $12,809,000 | -19.2% | 242,600 | +4.0% | 2.11% | -27.9% |
| SAGE | Buy | Sage Therapeutics Inc | $12,600,000 | +37.0% | 78,227 | +40.1% | 2.08% | +22.4% |
| HRTX | New | Heron Therapeutics Inc | $11,288,000 | – | 409,000 | +100.0% | 1.86% | – |
| CBAY | Buy | Cymabay Therapeutics Inc | $11,076,000 | +124.4% | 852,686 | +58.9% | 1.82% | +100.4% |
| CLLS | New | Cellectis SAsponsored ads | $10,485,000 | – | 332,754 | +100.0% | 1.73% | – |
| AKRXQ | New | Akorn Inc | $9,439,000 | – | 504,503 | +100.0% | 1.55% | – |
| BMRN | Buy | BioMarin Pharmaceutical Inccall | $8,731,000 | -5.5% | 107,700 | +4.0% | 1.44% | -15.6% |
| ARWR | New | Arrowhead Pharmaceuticals Inc | $8,033,000 | – | 1,114,097 | +100.0% | 1.32% | – |
| STML | New | Stemline Therapeutics Inc | $8,011,000 | – | 523,624 | +100.0% | 1.32% | – |
| SLGL | New | Sol-Gel Technologies Ltd | $5,334,000 | – | 517,873 | +100.0% | 0.88% | – |
| ABEO | New | Abeona Therapeutics Inc | $5,302,000 | – | 369,500 | +100.0% | 0.87% | – |
| PRGO | New | Perrigo Co PLC | $4,646,000 | – | 55,748 | +100.0% | 0.76% | – |
| CARA | New | Cara Therapeutics Inc | $4,346,000 | – | 351,050 | +100.0% | 0.72% | – |
| MDGL | New | Madrigal Pharmaceuticals Inc | $4,231,000 | – | 36,226 | +100.0% | 0.70% | – |
| ONCS | New | OncoSec Medical Inc | $3,881,000 | – | 2,064,297 | +100.0% | 0.64% | – |
| NLNK | New | NewLink Genetics Corpcall | $3,625,000 | – | 500,000 | +100.0% | 0.60% | – |
| ZSAN | New | Zosano Pharma Corp | $3,528,000 | – | 700,000 | +100.0% | 0.58% | – |
| ZFGN | Buy | Zafgen Inc | $2,992,000 | +277.8% | 401,558 | +134.2% | 0.49% | +237.7% |
| ADVM | New | Adverum Biotechnologies Inc | $2,907,000 | – | 501,183 | +100.0% | 0.48% | – |
| MNLO | New | Menlo Therapeutics Inc | $2,786,000 | – | 74,142 | +100.0% | 0.46% | – |
| XENE | New | Xenon Pharmaceuticals Inc | $1,857,000 | – | 379,071 | +100.0% | 0.31% | – |
| FIXX | New | Homology Medicines Inc | $243,000 | – | 13,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.